Bet v 1.0101
Escherichia Coli.
Greater than 95.0% as determined by SDS-PAGE.
Description
Recombinant Major pollen allergen Bet v 1-A produced in SF9 is a single, glycosylated polypeptide chain containing 167 amino acids (2-160a.a) and having a molecular mass of 18.5kDa (calculated). Bet v 1.0101 is fused to an 8 a.a on N-terminal.
Product Specs
Escherichia Coli.
MKHHHHHHGV FNYETETTSV IPAARLFKAF ILDGDNLFPK VAPQAISSVE NIEGNGGPGT IKKISFPEGF PFKYVKDRVD EVDHTNFKYN YSVIEGGPIG DTLEKISNEI KIVATPDGGS ILKISNKYHT KGDHEVKAEQ VKASKEMGET LLRAVESYLL AHSDAYN.
Product Science Overview
The major pollen allergen Bet v 1 is a well-known allergen derived from birch pollen (Betula verrucosa). It is a significant cause of allergic reactions, particularly in the temperate climate zones of the Northern Hemisphere. Bet v 1 is recognized by more than 90% of patients allergic to birch pollen . The recombinant form of Bet v 1, known as Bet v 1-A, has been extensively studied for its immunological properties and potential therapeutic applications.
The concept of allergies was first introduced in 1906 by Austrian scientist Clemens Freiherr von Pirquet. The journey towards understanding Bet v 1 began in earnest in the late 20th century. In 1983, Dietrich Kraft proposed replacing natural extracts used in allergy diagnostics with recombinant allergen molecules. This led to the cloning of the first plant allergen, Bet v 1, in 1989 .
Bet v 1 belongs to the PR-10-like protein family, which is part of the larger Bet v 1-like superfamily. This superfamily is characterized by a conserved fold present in all three domains of life: archaea, bacteria, and eukaryotes. The primary biological function of Bet v 1 is believed to be related to lipid binding. However, over time, the Bet v 1-like superfamily has evolved to include a diverse range of functions .
Recombinant Bet v 1 is produced using advanced molecular cloning techniques. The production process involves expressing the Bet v 1 gene in a suitable host organism, such as Escherichia coli, followed by purification of the protein. This recombinant form is used in various diagnostic and therapeutic applications, including allergen-specific immunotherapy (SIT). Studies have shown that the immunological behavior of recombinant Bet v 1 can be influenced by the production method, affecting its potential clinical applications .
Bet v 1 is a major allergen responsible for birch pollen allergy, which affects a significant portion of the population in Northern and Central Europe. The recombinant form of Bet v 1 is used in allergen-specific IgE antibody testing and has shown promise in allergen-specific immunotherapy. Recombinant Bet v 1 isoforms with low IgE binding properties are considered ideal candidates for desensitizing allergic patients .
